Browsing by Author "Lazo, Raul Luna"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Next-generation wound care: a scoping review on probiotic, prebiotic, synbiotic, and postbiotic cutaneous formulationsPublication . Machado, Patrícia; Ribeiro, Felipe Neme; Giublin, Fernanda Wroblevski; Mieres, Naomi Gerzvolf; Tonin, Fernanda; Pontarolo, Roberto; Sari, Marcel Marcondes; Lazo, Raul Luna; Ferreira, Luana MotaBackground/Objectives: Chronic wounds represent a significant socioeconomic burden, affecting 1–2% of the global population. Wound healing is a complex process involving inflammation, cell proliferation, and tissue remodeling, but factors such as infections, diabetes, aging, and poor nutrition can impair recovery, leading to chronic wounds. Given these challenges, researchers have explored topical probiotics, synbiotics, and postbiotics as alternative strategies. Strains like Lactobacillus and Bifidobacterium contribute to skin restoration by producing antimicrobial, anti-inflammatory, and immunomodulatory compounds, offering a novel approach to cutaneous restoration. Our study aims to address the potential effects of topical probiotic, synbiotic, and postbiotic formulations for wound healing applications by means of a broad scoping review and evidence-gap mapping. Methods: A systematic literature search of preclinical studies (in vitro and in vivo) was performed in PubMed, Scopus, and Web of Science (January 2025), yielding 3052 articles after duplicates removal, of which 44 met the inclusion criteria. Results: These studies were published between 1986 and 2024, mostly by China (27.3%) and Iran (25.0%). Probiotics were frequently evaluated among the studies included (47.7%) (with Lactobacillus plantarum being the most assessed strain), followed by postbiotics (36.4%) (with predominant use of cell-free supernatants) and synbiotics (15.9%) (especially fructooligosaccharides). Dosage forms included gels (44.4%), films (15.6%), and ointments (13.3%). Conclusions: Most studies indicate that probiotics, synbiotics, and postbiotics have antimicrobial and anti-inflammatory properties, while promoting angiogenesis, tissue regeneration, and skin barrier restoration. The use of different delivery systems may additionally enhance therapeutic outcomes by accelerating wound closure, reducing bacterial load, and modulating immune response. However, methodological limitations in animal studies highlight the need for greater experimental rigor. Further robust clinical trials are essential to confirm efficacy and safety before clinical application of these formulations.
- Safety profile of gestrinone: a systematic reviewPublication . Fagundes, Vitor Luís; Marques, Nathália Barreiro; Lima, Amanda Franco de; Cobre, Alexandre de Fátima; Tonin, Fernanda; Lazo, Raul Luna; Pontarolo, RobertoBackground: Gestrinone is a synthetic hormone derived from 19-nortestosterone, exhibiting androgenic, anabolic, anti-progestogenic, and antiestrogenic effects. Gestrinone subcutaneous implants have been used “off label” for aesthetic purposes due to their anabolic action, promoting accelerated metabolism and muscle gain. Objective: Our goal is to conduct a systematic review focused exclusively on identifying the safety profile of gestrinone use, without addressing efficacy. Methods: This systematic review was performed according to the Joanna Briggs Institute and Cochrane Collaboration recommendations and is reported following the Preferred Reporting Items for Systematic Reviews and Network Meta-Analyses. This article’s searches were carried out in the PubMed, Embase, and Web of Science databases. Results: A total of 32 articles were included in this study. The reported adverse events associated with the use of gestrinone were amenorrhea (41.4% of cases), acne, seborrhea (42.7% of reports), decreased libido (26.5%), and hot flushes (24.2%). Other nonspecific symptoms, such as hoarseness and cramps, were also fairly reported (3.5% and 18.6%, respectively). Other reported effects were associated with breast size reduction (23.7% of patients) and increased transaminases (15.1%). Most studies (40%, n = 24 studies) found significant weight gain (ranging from 0.9 to 8 kg per patient). Abnormalities in bone mineral density were reported in four studies. Conclusions: The evidence remains insufficient to fully understand the risks of gestrinone use associated with its widespread, unregulated use. Thus, further standardized studies and regulatory oversight to ensure patient safety are needed to mitigate potential health risks.